Esperion Therapeutics, Inc. (ESPR) intrinsic value & 10-year financials
Esperion Therapeutics, Inc. (ESPR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 18.1% a year to $403.1M, with an average return on invested capital of -0.3%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $403.1M
- Revenue growth (10-yr CAGR)
- 18.1%
- ROIC (10-yr avg)
- -0.3%
- Free cash flow (FY2025)
- -$13.1M
ESPR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $403.1M | -$22.7M | -$0.11 | -$13.1M | 15.0% | -12.1% |
| FY2024 | $332.3M | -$51.7M | -$0.28 | -$24.0M | 16.4% | -10.2% |
| FY2023 | $116.3M | -$209.2M | -$2.03 | -$135.5M | -133.7% | 31.7% |
| FY2022 | $75.5M | -$233.7M | -$3.52 | -$174.8M | -237.8% | 42.1% |
| FY2021 | $78.4M | -$269.1M | -$9.31 | -$263.8M | -289.0% | 56.5% |
| FY2020 | $227.5M | -$143.6M | -$5.23 | -$86.0M | -53.3% | 44.7% |
| FY2019 | $148.4M | -$97.2M | -$3.59 | -$71.3M | -62.8% | 64.2% |
| FY2018 | $0 | -$201.8M | — | -$148.8M | — | -96.8% |
| FY2017 | — | -$167.0M | — | -$131.3M | — | -83.6% |
| FY2016 | — | -$75.0M | — | -$47.8M | — | -39.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Esperion Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Esperion Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -0.3% ROIC.
Esperion Therapeutics, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Esperion Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3.65 per share.